NCS-382 is a moderately selective antagonist for the GHB receptor. It blocks the effects of GHB in animals and has both anti-sedative and anticonvulsant effects. It has been proposed as a treatment for GHB overdose in humans as well as the genetic metabolic disorder succinic semialdehyde dehydrogenase deficiency (SSADHD), but has never been developed for clinical use.
NCS-382 is a moderately selective antagonist for the GHB receptor. It blocks the effects of GHB in animals and has both anti-sedative and anticonvulsant effects. It has been proposed as a treatment for GHB overdose in humans as well as the genetic metabolic disorder succinic semialdehyde dehydrogenase deficiency (SSADHD), but has never been developed for clinical use.
==References==
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).